Canaccord Genuity Group Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $385.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price raised by Canaccord Genuity Group from $384.00 to $385.00 in a report published on Tuesday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also commented on the company. Barclays increased their […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price raised by Canaccord Genuity Group from $384.00 to $385.00 in a report published on Tuesday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also commented on the company. Barclays increased their […]
